Movement Alert｜Gilead Sciences Rises 3.05% in Regular Trading, Announces $7.8 Billion Acquisition of Arcellx to Bolster Oncology Pipeline

Market Focus08-18 23:33

On August 18, Gilead Sciences rose 3.05% in regular trading, trading at $143.155/share, with turnover of $235 million. The rally was driven by the company's announcement of a $7.8 billion equity-value acquisition of cancer therapy developer Arcellx.

Under the deal terms, Gilead will pay $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium to Arcellx's previous closing price. The acquisition is viewed as a strategic move to further strengthen Gilead's oncology pipeline, complementing its existing cell therapy assets including the Anito-Cel program approaching its FDA PDUFA date. The deal also follows the recent FDA approval of Trodelvy for first-line triple-negative breast cancer and an EMA recommendation for a Trodelvy-Keytruda combination.

Additionally, Gilead's most recent Q2 results showed revenue of $7.8 billion beating estimates of $7.4 billion, while full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, better than the consensus estimate of $0.75 loss, supported by HIV growth guidance raised to 9-10%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190093992?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190093992","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Gilead Sciences Rises 3.05% in Regular Trading, Announces $7.8 Billion Acquisition of Arcellx to Bolster Oncology Pipeline","media":"Market Focus","content":"<p><p>On August 18, Gilead Sciences rose 3.05% in regular trading, trading at $143.155/share, with turnover of $235 million. The rally was driven by the company's announcement of a $7.8 billion equity-value acquisition of cancer therapy developer Arcellx.</p><p>Under the deal terms, Gilead will pay $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium to Arcellx's previous closing price. The acquisition is viewed as a strategic move to further strengthen Gilead's oncology pipeline, complementing its existing cell therapy assets including the Anito-Cel program approaching its FDA PDUFA date. The deal also follows the recent FDA approval of Trodelvy for first-line triple-negative breast cancer and an EMA recommendation for a Trodelvy-Keytruda combination.</p><p>Additionally, Gilead's most recent Q2 results showed revenue of $7.8 billion beating estimates of $7.4 billion, while full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, better than the consensus estimate of $0.75 loss, supported by HIV growth guidance raised to 9-10%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Gilead Sciences Rises 3.05% in Regular Trading, Announces $7.8 Billion Acquisition of Arcellx to Bolster Oncology Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Gilead Sciences Rises 3.05% in Regular Trading, Announces $7.8 Billion Acquisition of Arcellx to Bolster Oncology Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-18 23:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 18, Gilead Sciences rose 3.05% in regular trading, trading at $143.155/share, with turnover of $235 million. The rally was driven by the company's announcement of a $7.8 billion equity-value acquisition of cancer therapy developer Arcellx.</p><p>Under the deal terms, Gilead will pay $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium to Arcellx's previous closing price. The acquisition is viewed as a strategic move to further strengthen Gilead's oncology pipeline, complementing its existing cell therapy assets including the Anito-Cel program approaching its FDA PDUFA date. The deal also follows the recent FDA approval of Trodelvy for first-line triple-negative breast cancer and an EMA recommendation for a Trodelvy-Keytruda combination.</p><p>Additionally, Gilead's most recent Q2 results showed revenue of $7.8 billion beating estimates of $7.4 billion, while full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, better than the consensus estimate of $0.75 loss, supported by HIV growth guidance raised to 9-10%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1190093992","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190093992","pubTimestamp":1787067227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 18, Gilead Sciences rose 3.05% in regular trading, trading at $143.155/share, with turnover of $235 million. The rally was driven by the company's announcement of a $7.8 billion...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"走势提醒|吉利德科学常规交易上涨 3.05%，宣布斥资 78 亿美元收购 Arcellx，以加强肿瘤管道","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"On August 18, Gilead Sciences rose 3.05% in regular trading, trading at $143.155/share, with turnover of $235 million. The rally was driven by the company's announcement of a $7.8 billion equity-value acquisition of cancer therapy developer Arcellx.Under the deal terms, Gilead will pay $115 per share in cash plus a $5 per share contingent value right, representing an 87% premium to Arcellx's previous closing price. The acquisition is viewed as a strategic move to further strengthen Gilead's oncology pipeline, complementing its existing cell therapy assets including the Anito-Cel program approaching its FDA PDUFA date. The deal also follows the recent FDA approval of Trodelvy for first-line triple-negative breast cancer and an EMA recommendation for a Trodelvy-Keytruda combination.Additionally, Gilead's most recent Q2 results showed revenue of $7.8 billion beating estimates of $7.4 billion, while full-year adjusted loss guidance was narrowed to $0.30-$0.65 per share, better than the consensus estimate of $0.75 loss, supported by HIV growth guidance raised to 9-10%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190093992","isCrawlerRequest":true}